title: Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
abstract: It was investigated whether human antibody against HIV-1 protein p17 (anti-p17) in HIV carriers' plasma has the ability to neutralize the infectivity of HIV. By the pretreatment of HIV-1 with anti-p17 from HIV carriers, progeny HIV-1 production from cells infected with virus pretreated with anti-p17 was suppressed and/or delayed. The neutralizing activity of anti-p17 was decreased in the presence of recombinant p17. The latter obviously masked the neutralizing activity of anti-p17. The relevant epitope(s) on p17 is located apparently on the surface of HIV virions and the binding of anti-p17 to p17 impairs the infectivity of HIV. This implies that anti-p17, if stably present in HIV carriers' plasma, may also play an important role in reducing the infectivity of HIV-1 in vivo.
authors.affiliation: Department of Virology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kageyama
authors.forename: T
authors.initials: T
authors.lastname: Katsumoto
authors.forename: K
authors.initials: K
authors.lastname: Taniguchi
authors.forename: S I
authors.initials: SI
authors.lastname: Ismail
authors.forename: T
authors.initials: T
authors.lastname: Shimmen
authors.forename: F
authors.initials: F
authors.lastname: Sasao
authors.forename: M
authors.initials: M
authors.lastname: Gao
authors.forename: S
authors.initials: S
authors.lastname: Owatari
authors.forename: N
authors.initials: N
authors.lastname: Wakamiya
authors.forename: H
authors.initials: H
authors.lastname: Tsuchie
authors.forename: S
authors.initials: S
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Shiraki
authors.forename: T
authors.initials: T
authors.lastname: Kurimura
mesh_terms: D000918:Antibody Specificity; D002353:Carrier State / Q000276:immunology*; D002461:Cell Line, Transformed; D015683:Gene Products, gag / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D006679:HIV Seropositivity / Q000097:blood / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology* / Q000648:ultrastructure; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D009500:Neutralization Tests; D014407:Tumor Cells, Cultured; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1